IP Library Granted Patent US 10,144,781
Granted Patent B2
US 10,144,781 · App. 15/610,417 · Granted Dec 4, 2018

Anti-CXCR4 antibodies and antibody-drug conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,144,781
App. No.
15/610,417
Granted
Dec 4, 2018
Kind
B2
Abstract

The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.

Claims (6)

1. An isolated polynucleotide comprising a nucleotide sequence encoding an antibody, or an antigen binding fragment thereof, that binds to chemokine receptor 4 (CXCR4) and comprises:

a) a heavy chain variable (VH) region comprising (i) a VH CDR1 comprising SEQ ID NO:107, 113, or 114; (ii) a VH CDR2 comprising SEQ ID NO: 162 or 128; and (iii) a VH CDR3 comprising SEQ ID NO: 112; and;

b) a light chain variable region (VL) region comprising (i) a VL CDR1 comprising SEQ ID NO: 144; (ii) a VL CDR2 comprising 145; and (iii) a VL CDR3 comprising SEQ ID NO: 139.

2. A vector comprising the polynucleotide of claim 1 .

3. An isolated host cell that recombinantly produces the antibody or antigen binding fragment thereof of claim 1 .

4. A method of producing an antibody or antigen binding fragment thereof, comprising culturing the host cell of claim 3 under conditions that result in production of the antibody or antigen binding fragment thereof, and isolating the antibody or antigen binding fragment thereof from the host cell or culture medium.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →